ALS biomarker research

ALS biomarker research using patient clinical samples

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051180229

Enrollment

Registered

2019-03-30

Start date

2019-04-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amyotrophic lateral sclerosis (ALS) ALS

Interventions

collection of cerebrospinal fluid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who agree to attend the current clinical study among ALS patients joining an accompanying clinical trial "Phase 1/2 Dose Escalation Study of Bostinib in Patients with Amyotrophic Lateral Sclerosis (ALS)"

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
Alteration of blood biomerkers including SOD1, TDP-43, Src, c-Abl, etc. Alteration of CSF biomerkers including neurofilament L, phosphorylated neurofilament H, SOD1, TDP-43, etc. Alteration of urine biomerkers including p75, etc. Plasma concentration of bosutinib (through value) CSF concentration of bosutinib (through value) Evaluation of biomerkers using iPS cells	—

Contacts

Public ContactHaruhisa Inoue

Kyoto University

prj-als_bosutinib@cira.kyoto-u.ac.jp+81-75-366-7360

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026